Siegfried Holding AG · SIX:SFZN
Siegfried — Merger or Acquisition (May 2015)
18 slides from Siegfried's merger presentation, May 7, 2015
Slide 1: Welcome
Welcome Media/Analyst Call Confidential
Slide 2: Media/Financial Analysts Call
Media/Financial Analysts Call Zofingen, May 7, 2015 Confidential Confidential
Slide 3: Important Notice
Important Notice This document is solely for use in connection with the presentation held by Siegfried Holding AG. It is furnished to you solely for your information and you may not reproduce it or redistribute to any other person. The contents of this document are to be kept strictly confidential b
Slide 4: Siegfried to acquire BASF's pharmaceutical supply business
Siegfried to acquire BASF's pharmaceutical supply business — The Siegfried Group signed an agreement with BASF to acquire significant segments of BASF’s pharmaceutical supply business for a total purchase price of EUR 270 million. — This business with sales of about CHF 280m and more than 800 employ
Slide 5: This transaction significantly improves Siegfried's valuation
This transaction significantly improves Siegfried`s valuation — EV and equity-value greatly improved — Purchase price based on an attractive EV/EBITDA Multiple — The transaction will be accretive from day one — The transaction will be accomplished through a smooth and concise signing/closing process
Slide 6: Acquisition financing without share capital increase
Acquisition financing without share capital increase — Siegfried has secured a bridge financing with two Swiss banks covering the acquisition price as well as current and future financing requirements — Subject to the closing of the acquisition, Siegfried has reached an agreement with these banks to
Slide 7: Closing of the deal currently expected for Q3
Closing of the deal currently expected for Q3 PMI preparation Integration 6 May 2015: Q3 2015: End of 2016: 2016: Signing Closing Condition for signing: Conditions for closing: Consultation of employees − Approval of merger in St.-Vulbas (expected control authorities duration of ~6 weeks) − Approval
Slide 8: Strategic fit (1/2): Strategic objectives have been successfully delivered
Strategic fit (1/2): Strategic objectives have been successfully delivered Defensive strategy Backward integration to Asia − Asset management, consolidation − Focus on improved cost position Achieve critical size − Top-line effect mainly as result of improved costs − Exploitation of synergies betwee
Slide 9: Strategic fit (2/2): Acquisition of BASF pharma supply business final M&A step
Strategic fit (2/2): Acquisition of BASF pharma supply business final M&A step as part of "TRANSFORM" strategy Overarching strategic goals: 1 Establish critical size — Extend total production capacity and diversify along therapeutic areas 2 Achieve competitive cost position — Realize network synergi
Slide 10: Deal rationale — overview: key reasons drive the acquisition
Deal rationale — overview: 4 key reasons drive the acquisition Category Rationale Reach required size to achieve a top industry position in Size/ Scale an increasingly consolidating industry and leverage flexibility to fulfill short-term orders (idle capacity) Sustainable Build a global growth platf
Slide 11: Deal rationale — Size/scale: Reach required size to achieve a top industry position
Deal rationale — Size/scale: Reach required size to achieve a top industry position Acquisition of Hameln Drug Acquisition of Alliance Pharmaceuticals GmbH and Medical Products Products Hameln RDS GmbH − Addition of sterile filling − Strengthening the develop- capabilities to advance ment and produc
Slide 12: Deal rationale — Siegfried becomes the industry-leading CMO (APIs)
Deal rationale — Size/ scale: Siegfried becomes the industry-leading CMO (APIs) # Players Selected Players Strategic <10 pharma partners Mid- Mid-sized standard ~50 suppliers "1- "1-project" CMO shops > 500 Confidential
Slide 13: Deal rationale — Siegfried becomes one of two important integrated partners
Deal rationale — Size/ scale: Siegfried becomes one of two important integrated partner of the pharma industry (Drug Substances + Drug Products) # Players Selected Players Strategic 2 pharma partners Mid- Mid-sized standard < 10 suppliers AAIPHARMA CAMBRIDGE MAJOR "1- "1-project" LABORATORIES shops
Slide 14: Summary: Siegfried to become the industry's preferred CMO
Summary: Siegfried to become the industry's preferred CMO Global efficient Critical size manufacturing >2,200 FTEs generating 9 production sites on sales > CHF600M 3 continents incl. Asia Leading Sustainable integrated CMO The 'new' 'new growth platform Integrated solutions in Diversified customer p
Slide 15: BASF CMO and API business at a glance: three dedicated, specialized sites
BASF CMO and API business at a glance: BASF pharma supply business operates three dedicated, specialized sites Site Key facts Key facts − cGMP manufacturing of customs active − FTE: ca. 350 pharmaceutical ingredients Evionnaz − Capacity: ca. 300m3 − Headquarter with all central functions − Global hu
Slide 16: BASF pharma supply business at a glance 2/2
BASF pharma supply business at a glance 2/2: BASF pharma supply business has a global footprint & diversified portfolio Key Facts Sales split Key Financials Sales split by client location Sales (CHF m) EBITDA- EBITDA-margin 0% ~280 57% 300 200 EBITDA- EBITDA-margin 34% 100 in the range of 15% 9% 0 S
Slide 17: Summary
Summary — ALIPHAT represents the final step in Siegfried’s TRANSFORM strategy implemented over the last five years. — The combination of Siegfried and the BASF pharma supply business creates the leading fully integrated outsourcing partner for the pharmaceutical industry. With total sales of over CH
Slide 18: Thank you for your attention
Thank you for your attention Media/Analyst Call Confidential